Bliss GVS Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE416D01022
NSEID: BLISSGVS
BSEID: 506197

INR

171.23

4.36 (2.61%)

BSENSE

Dec 05

BSE+NSE Vol: 75.42 lacs

{
  "main_header": {
    "sid": 730684,
    "name": "Bliss GVS Pharma",
    "stock_name": "Bliss GVS Pharma",
    "full_name": "Bliss GVS Pharma Ltd",
    "name_url": "stocks-analysis/bliss-gvs-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "171.23",
    "chg": 4.36,
    "chgp": "2.61%",
    "dir": 1,
    "prev_price": "166.87",
    "mcapval": "1,780.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506197,
    "symbol": "BLISSGVS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE416D01022",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "75.42 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bliss-gvs-pharma-730684-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Bliss GVS Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bliss-gvs-pharma-overvalued-or-undervalued-3747682",
        "imagepath": "",
        "date": "2025-12-05 08:29:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Health</strong></p>\n<p>Bliss GVS Pharma trades at a price-to-earnings (PE) ratio of approximately 16.35, which is moderate within the pharmaceutical sector. Its price-to-book value stands at 1.58, indicating the market values the company at nearly one and a half times its net asset value. The enterprise value to EBITDA ratio of 13.26 suggests a reasonable valuation relative to earnings before interest, tax, depreciation, and amortisation.</p>\n<p>Importantly, the company’s PEG ratio is below 1 at 0.92, signalling that its price is not excessively high relative to its earnings growth potential. However, the dividend yield is modest at 0.29%, which may be less attractive to income-focused investors.</p>\n<p>Return on capital employed (ROCE) and return on equity (R..."
      },
      {
        "title": "Bliss GVS Pharma Exhibits Bullish Momentum Amid Technical Parameter Revision",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-technical-momentum-shifts-to-bullish-amid-strong-price-gains-3747737",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BlissGVSPharma_technicaldot_3747737.png",
        "date": "2025-12-05 08:07:21",
        "description": "Bliss GVS Pharma has demonstrated a notable shift in price momentum following recent adjustments in its technical evaluation parameters. The pharmaceutical company’s shares have shown a bullish trend across multiple timeframes, supported by key indicators such as MACD, Bollinger Bands, and moving averages, signalling a potential strengthening in market sentiment."
      },
      {
        "title": "Why is Bliss GVS Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bliss-gvs-pharma-fallingrising-3747248",
        "imagepath": "",
        "date": "2025-12-05 00:55:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Intraday and Short-Term Price Momentum</strong></p>\n<p>The stock demonstrated remarkable strength on 04-Dec, opening with a 2% gap up and reaching an intraday high of ₹175.85, marking a 13.52% increase from the previous close. This surge reflects heightened investor interest and confidence in the stock’s near-term prospects. Over the last two trading sessions, Bliss GVS Pharma has delivered a cumulative return of 9.85%, underscoring a positive momentum that has outpaced its sector peers by 9.17% on the day. The wide trading range of ₹20.45 indicates active price discovery and volatility, which often accompanies strong buying interest.</p>\n<p><strong>Technical Strength Supported by Moving Averages</strong></p>\n<p>Technically, the stock is trading above all key moving averages, includin..."
      },
      {
        "title": "Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-hits-intraday-high-with-749-surge-on-4-dec-2025-3746739",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BlissGVSPharma_priceRelatedfactors_3746739.png",
        "date": "2025-12-04 12:11:24",
        "description": "Bliss GVS Pharma demonstrated robust intraday performance on 4 December 2025, surging to an intraday high of Rs 166.8, reflecting a 7.68% rise during the trading session. The stock outpaced its sector and broader market indices, supported by notable volatility and sustained buying interest throughout the day."
      },
      {
        "title": "Bliss GVS Pharma Technical Momentum Shifts Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-technical-momentum-shifts-amid-mixed-market-signals-3740206",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BlissGVSPharma_technicaldot_3740206.png",
        "date": "2025-12-02 08:08:10",
        "description": "Bliss GVS Pharma has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The pharmaceutical company’s stock price currently trades at ₹155.55, down from the previous close of ₹166.25, amid a broader market environment that has seen mixed returns compared to the Sensex benchmark."
      },
      {
        "title": "Bliss GVS Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bliss-gvs-pharma-upgraded-to-hold-by-marketsmojo-on-12-nov-2025-3736966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_mojoScore_3736966.png",
        "date": "2025-11-29 17:52:00",
        "description": "Bliss GVS Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of stable quality metrics, fair valuation, and bullish technical indicators, set against a backdrop of flat financial trends and modest market returns."
      },
      {
        "title": "Bliss GVS Pharma Shows Shift in Price Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-technical-momentum-shifts-signal-bullish-outlook-3727547",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_technicaldot_3727547.png",
        "date": "2025-11-25 08:09:12",
        "description": "Bliss GVS Pharma has exhibited a notable shift in its price momentum, reflecting a transition in technical parameters that suggest evolving market sentiment. Recent trading activity and technical indicators reveal a complex picture for this Pharmaceuticals & Biotechnology stock, with bullish trends emerging alongside some cautionary signals."
      },
      {
        "title": "Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bliss-gvs-pharma-hits-intraday-high-with-723-surge-on-24-nov-2025-3725680",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BlissGVSPharma_priceRelatedfactors_3725680.png",
        "date": "2025-11-24 14:02:15",
        "description": "Bliss GVS Pharma demonstrated robust intraday performance on 24 Nov 2025, reaching a day’s high of Rs 171.3, reflecting a gain of 7.16% amid a broadly positive market environment."
      },
      {
        "title": "Is Bliss GVS Pharma overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bliss-gvs-pharma-overvalued-or-undervalued-3716745",
        "imagepath": "",
        "date": "2025-11-20 08:06:21",
        "description": "As of 19 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a PE ratio of 15.51, an EV to EBITDA of 12.52, and a PEG ratio of 0.88, all of which suggest that it is trading at a discount compared to its peers.\n\nIn comparison to its industry peers, Bliss GVS Pharma's valuation metrics stand out positively. For instance, Sun Pharma has a significantly higher PE ratio of 37.07, while Divi's Lab is even more expensive at 68.85. Additionally, Cipla and Dr. Reddy's Labs, both classified as attractive, have PE ratios of 22.64 and 18.06, respectively. Despite a recent underperformance relative to the Sensex on a year-to-date basis, Bliss GVS Pharma has shown strong returns over the past year, outperforming the index with a return of 33.10% compared to 9.81% for the Se..."
      }
    ],
    "total": 269,
    "sid": "730684",
    "stock_news_url": "https://www.marketsmojo.com/news/bliss-gvs-pharma-730684"
  },
  "announcements": [
    {
      "details": "Bliss GVS Pharma Limited has informed the Exchange regarding 'Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement clippings of unaudited financial results of the Company for the second quarter and half year ended September 30, 2019 published in The Economic Times & The Free Press Journal an English Daily and Maharashtra Times & Navshkati a Regional Daily, on November 13, 2019.",
      "source": "NSE",
      "caption": "Bliss GVS Pharma Limited - Updates",
      "datetime": "13-Nov-2019"
    },
    {
      "details": "Bliss GVS Pharma Limited has informed the Exchange regarding 'Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Monday, November 11, 2019 at the registered office of the Company, inter-alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2019 published in The Economic Times an English Daily and Maharashtra Times a Regional Daily, on November 05, 2019.",
      "source": "NSE",
      "caption": "Bliss GVS Pharma Limited - Updates",
      "datetime": "05-Nov-2019"
    },
    {
      "details": "Bliss GVS Pharma Limited has informed the Exchange regarding a press release dated October 07, 2019, titled \"we enclose herewith Press Release announcing that Kremoint Pharma Private Limited, India, a 70% subsidiary of Bliss GVS Pharma Limited (BGPL) has received a compliant certification from the U.S. Food and Drug Administration (FDA) that was based on the inspection conducted at the Company s facility located at M.I.D.C, Ambernath (East), Thane-District.\".",
      "source": "NSE",
      "caption": "Bliss GVS Pharma Limited - Press Release",
      "datetime": "09-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has declared <strong>50%</strong> dividend, ex-date: 24 Jul 25",
          "dt": "2025-07-24",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08",
          "dt": "2008-03-11",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Bliss GVS Pharma Ltd has announced <strong>3:5</strong> bonus issue, ex-date: 26 Sep 08",
          "dt": "2008-09-26",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Bliss GVS Pharma overvalued or undervalued?

2025-12-05 08:29:01

Valuation Metrics and Financial Health

Bliss GVS Pharma trades at a price-to-earnings (PE) ratio of approximately 16.35, which is moderate within the pharmaceutical sector. Its price-to-book value stands at 1.58, indicating the market values the company at nearly one and a half times its net asset value. The enterprise value to EBITDA ratio of 13.26 suggests a reasonable valuation relative to earnings before interest, tax, depreciation, and amortisation.

Importantly, the company’s PEG ratio is below 1 at 0.92, signalling that its price is not excessively high relative to its earnings growth potential. However, the dividend yield is modest at 0.29%, which may be less attractive to income-focused investors.

Return on capital employed (ROCE) and return on equity (R...

Bliss GVS Pharma Exhibits Bullish Momentum Amid Technical Parameter Revision

2025-12-05 08:07:21

Bliss GVS Pharma has demonstrated a notable shift in price momentum following recent adjustments in its technical evaluation parameters. The pharmaceutical company’s shares have shown a bullish trend across multiple timeframes, supported by key indicators such as MACD, Bollinger Bands, and moving averages, signalling a potential strengthening in market sentiment.

Why is Bliss GVS Pharma falling/rising?

2025-12-05 00:55:05

Strong Intraday and Short-Term Price Momentum

The stock demonstrated remarkable strength on 04-Dec, opening with a 2% gap up and reaching an intraday high of ₹175.85, marking a 13.52% increase from the previous close. This surge reflects heightened investor interest and confidence in the stock’s near-term prospects. Over the last two trading sessions, Bliss GVS Pharma has delivered a cumulative return of 9.85%, underscoring a positive momentum that has outpaced its sector peers by 9.17% on the day. The wide trading range of ₹20.45 indicates active price discovery and volatility, which often accompanies strong buying interest.

Technical Strength Supported by Moving Averages

Technically, the stock is trading above all key moving averages, includin...

Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum

2025-12-04 12:11:24

Bliss GVS Pharma demonstrated robust intraday performance on 4 December 2025, surging to an intraday high of Rs 166.8, reflecting a 7.68% rise during the trading session. The stock outpaced its sector and broader market indices, supported by notable volatility and sustained buying interest throughout the day.

Bliss GVS Pharma Technical Momentum Shifts Amid Market Volatility

2025-12-02 08:08:10

Bliss GVS Pharma has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. The pharmaceutical company’s stock price currently trades at ₹155.55, down from the previous close of ₹166.25, amid a broader market environment that has seen mixed returns compared to the Sensex benchmark.

Bliss GVS Pharma Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-29 17:52:00

Bliss GVS Pharma's market evaluation has undergone a revision reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of stable quality metrics, fair valuation, and bullish technical indicators, set against a backdrop of flat financial trends and modest market returns.

Bliss GVS Pharma Shows Shift in Price Momentum Amid Mixed Technical Signals

2025-11-25 08:09:12

Bliss GVS Pharma has exhibited a notable shift in its price momentum, reflecting a transition in technical parameters that suggest evolving market sentiment. Recent trading activity and technical indicators reveal a complex picture for this Pharmaceuticals & Biotechnology stock, with bullish trends emerging alongside some cautionary signals.

Bliss GVS Pharma Hits Intraday High with Strong Trading Momentum

2025-11-24 14:02:15

Bliss GVS Pharma demonstrated robust intraday performance on 24 Nov 2025, reaching a day’s high of Rs 171.3, reflecting a gain of 7.16% amid a broadly positive market environment.

Is Bliss GVS Pharma overvalued or undervalued?

2025-11-20 08:06:21

As of 19 November 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, with a PE ratio of 15.51, an EV to EBITDA of 12.52, and a PEG ratio of 0.88, all of which suggest that it is trading at a discount compared to its peers. In comparison to its industry peers, Bliss GVS Pharma's valuation metrics stand out positively. For instance, Sun Pharma has a significantly higher PE ratio of 37.07, while Divi's Lab is even more expensive at 68.85. Additionally, Cipla and Dr. Reddy's Labs, both classified as attractive, have PE ratios of 22.64 and 18.06, respectively. Despite a recent underperformance relative to the Sensex on a year-to-date basis, Bliss GVS Pharma has shown strong returns over the past year, outperforming the index with a return of 33.10% compared to 9.81% for the Se...

View All News

Announcement

Bliss GVS Pharma Limited - Updates

13-Nov-2019 | Source : NSE

Bliss GVS Pharma Limited has informed the Exchange regarding 'Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement clippings of unaudited financial results of the Company for the second quarter and half year ended September 30, 2019 published in The Economic Times & The Free Press Journal an English Daily and Maharashtra Times & Navshkati a Regional Daily, on November 13, 2019.

Bliss GVS Pharma Limited - Updates

05-Nov-2019 | Source : NSE

Bliss GVS Pharma Limited has informed the Exchange regarding 'Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Monday, November 11, 2019 at the registered office of the Company, inter-alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2019 published in The Economic Times an English Daily and Maharashtra Times a Regional Daily, on November 05, 2019.

Bliss GVS Pharma Limited - Press Release

09-Oct-2019 | Source : NSE

Bliss GVS Pharma Limited has informed the Exchange regarding a press release dated October 07, 2019, titled "we enclose herewith Press Release announcing that Kremoint Pharma Private Limited, India, a 70% subsidiary of Bliss GVS Pharma Limited (BGPL) has received a compliant certification from the U.S. Food and Drug Administration (FDA) that was based on the inspection conducted at the Company s facility located at M.I.D.C, Ambernath (East), Thane-District.".